Overexpression of APE1 in cancer cell lines and tumour tissues from various sources including non-small cell lung cancer (NSCLC), colon, glioma, head and neck, breast, and its association with resistance to various anticancer drugs strongly establishes APE1 as a target for cancer therapy [28–36]. The gene discussed is APEX1; the disease is cancer.